CTTH - CTT Pharma Announces Australia Patent Approval
(TheNewswire)
Tampa, Florida, United States - TheNewswire - March 23, 2022 - CTT Pharmaceutical Holdings, Inc.( OTC: CTTH) has expanded its reach into additionalinternational markets with a successful patent application of its OralStrip drug delivery system in Australia. This patent covers our"Oral Strip" delivery system, which utilizes micelles todeliver accurate and reliable active ingredient dosages rapidly. Theapplication of micelles in drug delivery is a powerful alternative fordissolving hydrophobic drugs in aqueous environments, minimizing drugdegradation and loss, preventing harmful side effects, and increasingdrug bioavailability. This granted patent is ideal for variousmedical APIs, including cannabinoids, psychedelics, nicotine, etc.,for the market in Australia. By increasing our geographic footprint,CTT Pharma continues to pursue its new strategy of monetizing its IPthrough partnerships for its drug delivery technology in many of theworld's most rapidly growing markets.
“With Australia legalizing Medical Marijuana, thispresents an opportunity, as we are actively looking for partners tooffer a smoke-free alternative for patients in Australia,” said RyanKhouri, CEO of CTT Pharma.
CTT is a drug delivery technologycompany that successfully received Health Canada approval, after whichit brought its first product to market as cannabinoid-infused"Dissolve Strips". This successful launch sold out to only85,000 medical patients online with no advertising in several weeks.
CTT common shares trade on the OTCmarket in the United States under the symbol "CTTH".
Contact Ryan Khouri at 813-606-0060
Rkhouri@cttpharmaceuticals.com
Copyright (c) 2022 TheNewswire - All rights reserved.